Postmenopausal osteoporosis

References

• Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12(1):24–35
   PubMed Web of Science ®Google Scholar
• Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Ann Intern Med 1998; 129(2):81–8
   PubMed Web of Science ®Google Scholar
• Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997; 103(2A):20–6S
   Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312(7041):1254–9
   PubMed Web of Science ®Google Scholar
• Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338(11):736–46
   PubMed Web of Science ®Google Scholar
• Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98(4):331–5
   Google Scholar
• Dawson-Hughes B, Harris SS, Krall EA, Dallai GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337(10):670–6
   PubMed Web of Science ®Google Scholar
• Aloia JF, Vaswani A, Yeh JK, et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994; 120(2):97–103
   Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7):605–13
   PubMed Web of Science ®Google Scholar
• Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and vitamin D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial. Maturitas 1998; 31(1):45–54
   Google Scholar
• Recker RR, Davies KM, Dowd RM, et al. The effect of low- dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized controlled trial. Ann Intern Med 1999; 130(11):897–904
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348(9041):1535–41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24):2077–82
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000; 12(1):1–12
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282(14):1344–52
   PubMed Web of Science ®Google Scholar
• Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305(6853):556–61
   Google Scholar
• Silverman SL, et al. In program and abstracts of the 26th European Symposium on Calcified Tissues; May 7–11, 1999; Maastricht, The Netherlands. Abstract 0–26ccc
   Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282(7):637–45
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999; 281(23):2189–97
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84(9):3076–81
   PubMed Web of Science ®Google Scholar
• Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA 2000; 283(10):1318–21
   Google Scholar
• Sturtridge W, Lentie B, Hanley DA. The use of bone density measurement in the diagnosis and management of osteoporosis. Can Med Assoc J 1996; 155(7):924–9
   Google Scholar
• Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone denisty in elderly women. N Engl J Med 1993; 329(16):1141–6
   Google Scholar
• Stock JL, Bell NH, Chesnut CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103(4):291–7
   Google Scholar
• Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 1995; 10(11):1778–87
   Google Scholar
• Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157(22):2617–24
   PubMed Web of Science ®Google Scholar